30 results about "Pain chronic" patented technology

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

A method and system for differentiating acute and chronic pain based on the functional state of specific neural circuits is proposed. This method utilizes in vivo two-photon / endoscopic calcium imaging and ex vivo brain slice patch-clamp techniques to longitudinally monitor the activity dynamics of neurons in the DRN and ZI brain regions during the acute and chronic phases of a neuropathic pain model. By extracting and analyzing calcium and electrophysiological signal parameter sets, distinguishing criteria are established: if the activity of 5-HTergic neurons in the DRN is specifically enhanced in the acute phase, the indication is acute pain; if the activity of GABAergic neurons in the ZI is specifically enhanced in the chronic phase, the indication is chronic pain. This invention achieves an objective and precise differentiation of the transition from acute to chronic pain at the level of specific neural circuits, providing a new strategy and tool for pain mechanism research and clinical diagnosis and treatment.

This disclosure relates to compounds of formula I (wherein X and R1-R4, n and m have the meanings set forth herein) and pharmaceutically acceptable salts thereof. Compounds of formula I exhibit GPR183 antagonist activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases for which GPR183 antagonists have been shown to be useful, such as chronic pain, e.g., osteoarthritis, chronic low back pain, neuropathic pain, and immune system disorders, e.g., inflammatory bowel diseases such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, e.g., asthma, and psoriasis. TIFF2026522963000085.tif2570

The application discloses a physical treatment equipment for island high-humidity environment and chronic pain, which comprises a host provided with a protective shell, a composite treatment electrode connected with the host, and a control system built in the host. The composite treatment electrode is provided with an electrically conductive part, a heating part, an impedance monitoring unit and a micro-environment humidity sensor. The control system comprises a cause identification module, a generation module and a treatment output module. The cause identification module is used for collecting and processing the skin impedance data of the impedance monitoring unit and the humidity data of the micro-environment humidity sensor, and identifying the identification cause causing the impedance change as biological sweating or environmental salt mist penetration. The generation module generates a corresponding first adjustment strategy or a second adjustment strategy according to the identification cause. The treatment output module is used for driving the electrically conductive part and the heating part of the composite treatment electrode to execute corresponding electric stimulation and heat therapy output based on the first adjustment strategy or the second adjustment strategy. The application not only has the protective shell for preventing corrosion, but also can adaptively adjust and match the treatment parameters in the island environment.

A device, system and method for the delivery of electrical stimulation for the treatment of acute or chronic pain and / or for the improvement of body function. There is described a neuromodulation electrode device including a substrate having a skin-facing surface and an electrode having at least one convex active surface projecting from the skin-facing surface of substrate for applying an electrical stimulation signal. A conductive gel layer having an electrode portion overlies the convex active surface(s) of the electrode. The substrate is formed of a conductive gel or the conductive gel layer further includes a substrate portion overlying the skin-facing surface of the substrate. The device further includes an isolating frame surrounding the perimeter of the electrode to provide electrical isolation between the electrode and the conductive gel substrate or from the substrate portion of the conductive gel layer.

The present invention relates to a synergistic admixture of Gabapentin and Ketoprofen, preferably Ketoprofen Lysine, to a pharmaceutical composition comprising said admixtures and to the use of said admixtures or pharmaceutical compositions in the treatment of acute or chronic pain, in particular in the treatment of neuropathic or inflammatory pain.

Provided are methods for preventing or treating a chronic pain in a subject that includes administering an effective amount of a composition of Lactococcus lactis DSM 27109 to the subject.

The present application belongs to the technical field of biological medicine, and particularly relates to a new use of a 5-HT6 receptor agonist in the preparation of a medicine for treating chronic pain complicated with anxiety and depression, and especially an application of the 5-HT6 receptor agonist in the preparation of a medicine for simultaneously treating chronic neuropathic pain and relieving anxiety and / or depression caused by the chronic pain. The present application discloses for the first time that in a pathological state of chronic pain (such as trigeminal neuralgia) secondary anxiety / depression, the expression of 5-HT6R in the mPFC brain region is significantly down-regulated, and a 5-HT6R agonist can dose-dependently specifically relieve anxiety / depression-like behaviors induced by chronic pain, and has no obvious effect on the behavior of normal animals, which indicates that the 5-HT6R agonist has good safety and targeting, and provides a theoretical basis for developing more effective medicines in the clinic.

This invention belongs to the field of biomedical technology, specifically relating to an ointment and its application. The toad oil used in this invention differs significantly in composition from toad venom, and its ointment is effective for various acute and chronic pain conditions. Animal experiments have confirmed that the toad oil ointment significantly reduces the frequency and delays the onset of acetic acid-induced writhing responses, demonstrating a clear analgesic effect. Clinical studies have shown that this ointment is rapidly effective and has a definite therapeutic effect on acute gout attacks, postherpetic neuralgia, and arthritis-related pain and swelling. The formulation effectively improves drug retention and user comfort, and no skin irritation has been observed. This development achieves comprehensive utilization of toad resources, providing an example for the sustainable development of traditional Chinese medicine and the efficient utilization of biological resources.

Methods, systems, and devices include processing one or more inputs including at least one of patient-provided answers and device utilization information in association with at least one health domain, wherein the at least one health domain is associated with one or more chronic conditions, determining one or more states of a patient in association with the at least one health domain based at least in part on processing the one or more inputs, and storing information describing the one or more states in an electronic data record.

The present invention relates to a therapeutic compound, a novel RNA interference (RNAi) agent, that reduces the expression of the voltage-gated sodium channel α subunit 10 (SCN10A) gene, which encodes Nav1.8 or a subunit of the Nav1.8 sodium channel. Such RNAi agents reduce the level of intact Nav1.8 sodium channels and are useful in the treatment of diseases in which the regulation of SCN10A expression and function is involved, such as chronic pain.

The application belongs to the technical field of biological medicine, and particularly relates to the use of SH2 domain-containing protein tyrosine phosphatase 1 (SHP1) in the preparation of a drug for treating chronic pain, in particular to the use of SHP1 in the preparation of a drug for treating chronic pain by regulating the morphology of spinal cord astrocytes, the integrity of the blood-spinal cord barrier and the STAT1-CXCL10-CXCR3 neuroimmune signal axis, and a chronic pain treatment strategy based on the signal axis. The application first discloses that SHP1 in spinal cord astrocytes directly dephosphorylates STAT1, inhibits the transcription of CXCL10 and the subsequent infiltration of T lymphocytes into the spinal cord, and discloses the core analgesic mechanism, thereby establishing SHP1 as a new target for treating chronic pain, and opening up a new way for the precise treatment of clinical chronic pain, especially neuropathic pain.

Embodiments of a method for treating a patient suffering from chronic pain are described. A source location of chronic pain in a patient is first identified. A regional anaesthetic is then used to temporarily block selected nerves to confirm the source location and identify a target nerve. An electrode array of a neuromodulation apparatus is then implanted in the patient over the target nerve, such as just under the stratum corneum, and the neuromodulation apparatus is then used to stimulate the electrode array to create a long term conduction block that provides persistent pain relief to the patient.

This invention discloses a wearable multimodal physical stimulation control method and device for chronic pain management, belonging to the field of wearable stimulation device technology. It includes setting intensity levels for different stimulation modes; collecting feedback data and establishing an optimal stimulation mode through a mode determination method; prioritizing stimulation modes other than the dominant stimulation mode under the optimal stimulation mode and determining stimulation parameters; during stimulation, adjusting different stimulation modes based on feedback data and priority ranking, and updating stimulation parameters; when the user adjusts the intensity level of the dominant stimulation mode, first determining temporary stimulation parameters, using these temporary parameters for stimulation while updating the stimulation parameters through feedback adjustment. This invention produces the most direct pain management effect on different causes of pain through different dominant stimulation modes, and achieves multimodal fusion stimulation by employing multiple different auxiliary stimulation modes, improving analgesic effects and relieving discomfort symptoms.

The present application relates to a pharmaceutical composition for treating chronic pain and pain-related memory impairment diseases, and belongs to the technical field of biological medicine. Through animal experiments, it is confirmed that the expression of C3 in the hippocampal area of chronic pain mice is increased, and exogenous C3 injection can induce pain and memory impairment phenotype. The present application proposes to use C3-C3aR inhibitors, such as small molecule inhibitor SB290157, to block the pathway. The pharmaceutical composition can be administered by systemic injection or targeted brain region administration to achieve intervention. C3aR inhibitors can simultaneously improve pain behavior and memory function in SNI model mice. By regulating the C3-C3aR signaling pathway in the hippocampal area, the present application directly acts on the pathological core link of pain-memory comorbidity, and provides a small molecule targeted treatment path for chronic pain patients.

Methods and systems are provided for diagnosing chronic spinal pain of a patient that include receiving and storing an image of the patient's back or neck. The image includes a first set of visual indicia corresponding to anatomical landmarks of the patient's back or neck as well as a second set of visual indica corresponding to locus of pain experienced by the patient. The image is processed to generate feature data representing spatial location and pain characteristics of point(s) corresponding to locus of pain experienced by the patient. The feature data is input to an expert system that generates first output data representing a predicted diagnosis of chronic pain of the patient and optional second output data representing a confidence level associated with the predicted diagnosis as indicated by the feature data input. A lookup table provides a treatment corresponding to the first output data and the optional second output data.

This invention discloses a zinc-quercetin nanocomposite, its preparation method, and its pharmaceutical applications, belonging to the field of bionanomaterials technology. This nanoparticle employs a carrier-free self-assembly strategy, directly forming a structurally stable nanocomposite by combining the natural flavonoid quercetin with zinc ions through metal-organic coordination bonds. This technology effectively overcomes the inherent defects of poor water solubility and low bioavailability of quercetin monomers, resulting in a nanocomposite with good water solubility and physiological stability. Simultaneously, zinc ions, as a key trace element for neuroregulation, can intervene in pain transmission pathways to alleviate pain; quercetin exerts a long-lasting anti-inflammatory and analgesic effect by continuously scavenging reactive oxygen species and inhibiting the release of inflammatory factors in damaged nerves or inflammatory sites. The two work synergistically in the lesion microenvironment, achieving the prevention and efficient, safe treatment of chronic pain. The preparation process is extremely simple, requiring no complex carriers, and has broad prospects for clinical translation and application.

The present invention relates to a nasal spray composition comprising CBD and one or more permeation enhancers that provide good sprayability, CBD solubility, composition stability, and enhanced bioavailability of the composition, so that the composition discloses a good spray plume during application. The present invention further discloses the use of such composition in the manufacture of a medicament for aiding in the treatment of anxiety, depression and chronic pain.

Methods and systems are provided for diagnosing chronic spinal pain that include receiving and storing an image of a patient's back or neck. The image includes a first set of visual indicia corresponding to anatomical landmarks of the patient's back or neck as well as a second set of visual indica corresponding to locus of pain experienced by the patient. The image is processed to generate feature data representing spatial location and pain characteristics of point(s) corresponding to locus of pain experienced by the patient. The feature data is input to an expert system that generates output data representing a predicted diagnosis of chronic pain of the patient and optional output data representing a confidence level associated with the predicted diagnosis as indicated by the feature data input. A lookup table provides a treatment corresponding to the output data.

The present invention discloses the use of a mRNA pain therapy to produce endogenous opioids for the treatment of temporary and chronic pain. In the preferred embodiment mRNA that encodes the production of B-endorphin, dynorphins A and B, and Nociceptin / Orphanin FQ, along with preferred packaging and administration options is disclosed.

This invention discloses a model, system, and device for predicting the risk of chronic postoperative pain after surgery in adolescents with idiopathic scoliosis, belonging to the field of medical decision support technology. This application provides the first CPSP prediction model integrating psychological and physical factors, and a risk assessment system built based on this model. By acquiring relevant patient parameters, it can calculate an individualized probability of chronic postoperative pain risk and further output risk levels and personalized perioperative management recommendations. This invention is the first to integrate psychological factors (depressive symptoms) with physiological factors (gender, surgical extent, etc.) to construct a prediction model, which has been verified to have excellent discriminative power (AUC up to 0.852), enabling rapid and accurate preoperative identification of high-risk patients and providing a usable decision support tool for clinical implementation of integrated "psychological-pain" interventions.

A method to alleviate chronic pain in humans and animals is disclosed. It comprises administering to said subject p62 / SQSTM1 polypeptide, p62 / SQSTM1 encoding nucleic acid, or mesenchymal stem cells expressing a p62-encoding vector or pretreated to increase the level of p62 protein encoded by the cell's chromosome or secretome from such cells.

This invention provides therapeutically active compounds useful for inhibiting the transcription-promoting domain (TEAD). [Solution] This invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) has utility as an inhibitor of TEAD. This compound is useful as a pharmaceutical in the treatment of diseases or conditions in which inhibition of TEAD is desired, such as cancer and chronic pain. TIFF2026086790000344.tif3158

The application belongs to the field of pharmaceutical chemistry, and particularly relates to a Tropomyosin Receptor Kinase A (TrkA) inhibitor and a preparation method and application thereof, a structural formula of which is shown as formula (I); the compound provided by the application has high inhibitory activity on TrkA and good subtype selectivity. The compound has potential application in analgesic treatment, including but not limited to chronic pain caused by osteoarthritis, cancer pain, back pain and the like; the compound also has potential anticancer activity.

Systems and techniques are disclosed to establish programming of an implantable electrical neurostimulation device for treating chronic pain of a human subject, through the use of a dynamic model adapted to determine pain treatment parameters for a human patient and identify a new device operational program to implement the pain treatment parameters to address the chronic pain condition. In an example, the system to establish programming of the neurostimulation device performs operations that: obtain state data indicating a measured value that is correlated to pain experienced by the human subject; determine neurostimulation programming parameters, using a dynamic model, for pain treatment in the human subject, as the dynamic model is used to identify values of the neurostimulation programming parameters that predict an improvement to the measured value; and indicate a neurostimulation program for the neurostimulation device, that includes the neurostimulation programming parameters for the implantable electrical neurostimulation device.

This invention discloses a machine learning-based method for predicting postoperative pain and extracting high-risk factors after cesarean section, belonging to the field of postoperative pain detection technology. It involves a unified modeling of static variables such as preoperative and intraoperative demographic characteristics, medical history, and surgical parameters, along with dynamic variables such as physiological monitoring indicators and analgesia intervention data obtained at different postoperative recovery stages. A two-branch prediction model with a static coding branch and a dynamic evolution branch is constructed. After model training, the SHAP attribution algorithm is introduced to interpret and analyze the prediction model, decomposing the model output into the contribution of each input variable to the prediction result, thereby quantifying the influence of each factor on pain risk. This invention utilizes a recurrent neural network to model the dynamic feature sequence that changes over time, enabling the model to learn the evolutionary pattern of postoperative pain as it changes with the recovery stage, improving the accuracy and stability of chronic pain risk prediction.

The present application provides a programmed drug release composite microneedle, which is composed of a drug-loaded needle tip layer and a base layer, can realize rapid release of analgesic drugs and slow release of sedative drugs, and the two drugs synergistically play the roles of analgesia, sedation and improvement of mood; through a plurality of experiments, it is verified that the microneedle has good biocompatibility, no skin irritation, no long-term toxicity to main organs, and non-invasive and convenient operation, solves many defects of traditional analgesic and sedative dosage forms, and provides a new effective path for long-term home intervention of chronic pain patients.

The application discloses a low-stimulus and high-safety benzoyl aconine original base temperature-sensitive analgesic gel injection as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The injection takes benzoyl aconine original base as a core analgesic component, constructs a triple heart protection system of'sub-anesthetic dose lidocaine + ammonium glycyrrhizinate + magnesium sulfate', cooperates with a poloxamer 407 temperature-sensitive gel matrix, and is supplemented with a cosolvent and an antioxidant, has a pH value of 5.5-6.5, can be injected at room temperature, and is quickly gelled at body temperature to realize long-acting controlled release. The preparation has high analgesic intensity, no addiction, slight injection pain, controllable cardiotoxicity, and can maintain analgesia for more than 12 hours after single administration, is suitable for local targeted treatment of moderate and severe chronic pain, neuropathic pain and the like, and has significant clinical advantages and popularization value.